Katherine Esposito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine Esposito has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Dario Giugliano
Department of Advanced Medical and Surgical Science, University of Campania “Luigi Vanvitelli”, Naples, Italy
9 shared publications - Annamaria De Bellis
Unit of Endocrinology and Metabolic Diseases, University of Campania “Luigi Vanvitelli”, Naples, Italy
3 shared publications - Giuseppe Bellastella
Division of Endocrinology and Metabolic Diseases University of Campania “Luigi Vanvitelli” Naples Italy
3 shared publications - Lorenzo Scappaticcio
Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
3 shared publications - Maria Ida Maiorino
Division of Endocrinology and Metabolic Diseases University of Campania “Luigi Vanvitelli” Naples Italy
3 shared publications Francesco Giugliano
Department of Geriatrics and Metabolic Diseases, Division of Metabolic Diseases, Second University of Naples , Naples , Italy
2 shared publications
Latest Publications
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
EMPATHY: a new tool for identifying the most suitable thyroxin formulation in hypothyroid patients
Hypothyroidism therapy is based on the administration of appropriate dose of L-thyroxine (L-T4). Absorption of L-T4 takes place in the duodenum and upper tract of the small intestine (jejunum), is maximal when stomach is empty, and is affected by a number of gastrointestinal disorders, including Helicobacter pylori–related gastritis, as well as ingestion of drugs, dietary fibers, and herbal remedies. Failure to achieve a good control of disease may be due to malabsorption in 40% of cases, or to poor compliance to L-T4 therapy in 60% of cases. During the past few years, various L-T4 formulations (in tablets, soft-gel capsules and liquid solution) have become available for clinical use. Liquid or gel formulations may be considered in subjects with hampered L-T4 absorption or who are not adherent to breakfast waiting time after L-T4 administration. Questionnaires to assess adherence to therapies are available and also adapted to patients with hypothyroidism. On the contrary, there are no tools available to detect malabsorption disorders and then addressing the endocrinologist in choosing the most appropriate therapy. Here we present EMPATHY (Evaluation of Malabsorption in PATients with HYpothyroidism): a questionnaire consisting of 13 questions which may help the endocrinologist to identify malabsorption disorders and then choose the most appropriate L-T4 formulation for each patient. EMPATHY allows to evaluate not only lactose and gluten intolerances but also some other allergies (nickel, histamine, citric acid, cornstarch) and alcohol intolerance. We administered EMPATHY to 150 newly diagnosed hypothyroid patients (50 males and 100 females). Exclusion criteria were previous thyroidectomy for thyroid cancer, central hypothyroidism, diabetes, obesity, current L-T4 therapy and pregnancy. We recorded more than 3 dose adjustments in six months in 21 out of 150 (14%) patients completing questionnaire and in 42 out of 150 (28%) not completing questionnaire (P=0.01). After two months of replacement therapy, most of patients in the group completing questionnaire (110 out of 150, 73%) and 82 out of 150 (54%) in the other group achieve a good control of disease (P=0.001). EMPATHY resulted extremely useful in the clinical practice allowing a better personalization of L-T4 replacement therapy and then a more rapid achievement of good control of the disease with smaller need of subsequent dose adjustments.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
EMPATHY: a new tool for identifying the most suitable thyroxin formulation in hypothyroid patients
Hypothyroidism therapy is based on the administration of appropriate dose of L-thyroxine (L-T4). Absorption of L-T4 takes place in the duodenum and upper tract of the small intestine (jejunum), is maximal when stomach is empty, and is affected by a number of gastrointestinal disorders, including Helicobacter pylori–related gastritis, as well as ingestion of drugs, dietary fibers, and herbal remedies. Failure to achieve a good control of disease may be due to malabsorption in 40% of cases, or to poor compliance to L-T4 therapy in 60% of cases. During the past few years, various L-T4 formulations (in tablets, soft-gel capsules and liquid solution) have become available for clinical use. Liquid or gel formulations may be considered in subjects with hampered L-T4 absorption or who are not adherent to breakfast waiting time after L-T4 administration. Questionnaires to assess adherence to therapies are available and also adapted to patients with hypothyroidism. On the contrary, there are no tools available to detect malabsorption disorders and then addressing the endocrinologist in choosing the most appropriate therapy. Here we present EMPATHY (Evaluation of Malabsorption in PATients with HYpothyroidism): a questionnaire consisting of 13 questions which may help the endocrinologist to identify malabsorption disorders and then choose the most appropriate L-T4 formulation for each patient. EMPATHY allows to evaluate not only lactose and gluten intolerances but also some other allergies (nickel, histamine, citric acid, cornstarch) and alcohol intolerance. We administered EMPATHY to 150 newly diagnosed hypothyroid patients (50 males and 100 females). Exclusion criteria were previous thyroidectomy for thyroid cancer, central hypothyroidism, diabetes, obesity, current L-T4 therapy and pregnancy. We recorded more than 3 dose adjustments in six months in 21 out of 150 (14%) patients completing questionnaire and in 42 out of 150 (28%) not completing questionnaire (P=0.01). After two months of replacement therapy, most of patients in the group completing questionnaire (110 out of 150, 73%) and 82 out of 150 (54%) in the other group achieve a good control of disease (P=0.001). EMPATHY resulted extremely useful in the clinical practice allowing a better personalization of L-T4 replacement therapy and then a more rapid achievement of good control of the disease with smaller need of subsequent dose adjustments.
- 4 December 2017
- Published by Springer Nature in L'Endocrinologo
- Vol. 18 (6) , 301-302
Insulinoma: il valore diagnostico della PET-TC 64Cu-Dotanoc
- 4 December 2017
- Published by Springer Nature in L'Endocrinologo
- Vol. 18 (6) , 301-302
Insulinoma: il valore diagnostico della PET-TC 64Cu-Dotanoc
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Natural history of autoimmune primary ovarian insufficiency progresses through several stages from normal ovary function to clinically overt ovary dysfunction
Context: Women with autoimmune Addison’s disease with normally ovulatory cycles but positive for steroid cells antibodies (StCA) have been considered at risk of premature ovarian insufficiency (POI). Design: Thirty-three women younger than 40 years, with subclinical-clinical Addison’s disease but with normally ovulatory menses, were followed-up for 10 years to evaluate the long-term time-related variations of StCA, ovarian function and follicular reserve. All patients and 27 control women were investigated at start and every year for the presence and titer of StCA (by indirect immunofluorescence), serum concentrations of anti-Mullerian hormone (AMH) and ovarian function along four consecutive menses every year. Results: At start of the study StCA were present in 16 women (group 1), at low/middle titer (≤1:32) in seven of them (43.75%, group 1A), at high titer (>1:32) in the remaining nine patients (group 1B, 56.2%), while they were absent in 17 patients (group 2). During the follow-up period, all women in group 1A persisted StCA positive at low/middle titer with normal ovulatory menses and normal gonadotropin and AMH levels, while all patients in group 1B showed a further increase of StCA titers (1:128–1:256) and progressed through three stages of ovarian function. None of patients in group 2 and controls showed appearance of StCA or ovary dysfunction during the follow-up. Conclusions: The presence of StCA at high titers could be considered a good predictive marker of subsequent development of autoimmune POI. To single out the stages of autoimmune POI may allow a timely therapeutic choice in subclinical and early clinical stage.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Natural history of autoimmune primary ovarian insufficiency progresses through several stages from normal ovary function to clinically overt ovary dysfunction
Context: Women with autoimmune Addison’s disease with normally ovulatory cycles but positive for steroid cells antibodies (StCA) have been considered at risk of premature ovarian insufficiency (POI). Design: Thirty-three women younger than 40 years, with subclinical-clinical Addison’s disease but with normally ovulatory menses, were followed-up for 10 years to evaluate the long-term time-related variations of StCA, ovarian function and follicular reserve. All patients and 27 control women were investigated at start and every year for the presence and titer of StCA (by indirect immunofluorescence), serum concentrations of anti-Mullerian hormone (AMH) and ovarian function along four consecutive menses every year. Results: At start of the study StCA were present in 16 women (group 1), at low/middle titer (≤1:32) in seven of them (43.75%, group 1A), at high titer (>1:32) in the remaining nine patients (group 1B, 56.2%), while they were absent in 17 patients (group 2). During the follow-up period, all women in group 1A persisted StCA positive at low/middle titer with normal ovulatory menses and normal gonadotropin and AMH levels, while all patients in group 1B showed a further increase of StCA titers (1:128–1:256) and progressed through three stages of ovarian function. None of patients in group 2 and controls showed appearance of StCA or ovary dysfunction during the follow-up. Conclusions: The presence of StCA at high titers could be considered a good predictive marker of subsequent development of autoimmune POI. To single out the stages of autoimmune POI may allow a timely therapeutic choice in subclinical and early clinical stage.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes
Diurnal salivary and plasma cortisol variations are considered valid expression of circadian cortisol rhythmicity. The aim of this study was to assess the reliability of salivary and plasma cortisol evaluating if glycemia and glycemic oscillations may interfere with their concentration. Methods: Forty-seven type 2 diabetic patients and 31 controls were studied for glycemic profile and diurnal salivary and plasma cortisol variations on two contemporary samples taken at 0800 and 2300 h (Late Night, LN). Glucose variability was evaluated in diabetic patients by considering the standard deviation of blood glucose (BGSD) readings, by calculating the mean amplitude of glycemic excursions (MAGEs) and continuous overlapping net glycemic action (CONGA). Results: A significant correlation between LN serum cortisol and morning fasting glycemia (r=0.78; P=0.004) was observed in T2DM group but not in the control group (r=0.09; P=0.74). While LN serum cortisol significantly correlated with CONGA in diabetic patients (r=0.50; Pr=0.80; Pr=0.07; P=0.62). Conclusions: This study shows for the first time that late night salivary cortisol may give more information than late night plasma cortisol on the dynamic of adrenal function of type 2 diabetic patients, as it is not significantly influenced by glycemic variations.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes
Diurnal salivary and plasma cortisol variations are considered valid expression of circadian cortisol rhythmicity. The aim of this study was to assess the reliability of salivary and plasma cortisol evaluating if glycemia and glycemic oscillations may interfere with their concentration. Methods: Forty-seven type 2 diabetic patients and 31 controls were studied for glycemic profile and diurnal salivary and plasma cortisol variations on two contemporary samples taken at 0800 and 2300 h (Late Night, LN). Glucose variability was evaluated in diabetic patients by considering the standard deviation of blood glucose (BGSD) readings, by calculating the mean amplitude of glycemic excursions (MAGEs) and continuous overlapping net glycemic action (CONGA). Results: A significant correlation between LN serum cortisol and morning fasting glycemia (r=0.78; P=0.004) was observed in T2DM group but not in the control group (r=0.09; P=0.74). While LN serum cortisol significantly correlated with CONGA in diabetic patients (r=0.50; Pr=0.80; Pr=0.07; P=0.62). Conclusions: This study shows for the first time that late night salivary cortisol may give more information than late night plasma cortisol on the dynamic of adrenal function of type 2 diabetic patients, as it is not significantly influenced by glycemic variations.
- 1 August 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 97 (2) , 175-177
Diabetes medications and cancer: A way out of uncertainty
- 1 August 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 97 (2) , 175-177
Diabetes medications and cancer: A way out of uncertainty
- 30 June 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 96 (3) , 414-415
HbA1c targets for type 2 diabetes: How many, …how far!
- 30 June 2012
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 96 (3) , 414-415
HbA1c targets for type 2 diabetes: How many, …how far!
- 8 June 2009
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 169 (11) , 1069
Which Mediterranean Diet in the Management of Metabolic Syndrome?
- 8 June 2009
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 169 (11) , 1069
Which Mediterranean Diet in the Management of Metabolic Syndrome?
- 1 June 2008
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 5 (6) , 1436-1442
Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction
Endothelial microparticles (EMPs) may play a role as biomarkers of vascular injury. EMPs are higher in men with diabetes diabetic men with erectile dysfunction (ED) than in nondiabetic potent men. The aim of this study was to quantize different phenotypic circulating EMP levels among diabetic and nondiabetic patients with ED, and to determine whether EMPs are released as a result of activation or apoptosis. We studied 30 type 2 diabetic and 24 nondiabetic subjects with symptomatic ED from at least 6 months, and 20 nondiabetic men without ED matched for age and weight with diabetic and nondiabetic subjects. Erectile function was assessed by completing the International Index of Erectile Function (IEEF)-5, which consists of Items 5, 15, 4, 2, and 7 from the full-scale IIEF-15. A score of 21 or less indicates the presence of ED. EMP levels in plasma were quantified by flow cytometry. Markers for apoptosis (platelet/endothelial cell adhesion molecule 1/CD31 antigen) and activation (E-selectin/CD62E antigen) were compared. Endothelium-dependent flow-mediated dilation (FMD) was evaluated in the right brachial artery with a high-resolution ultrasound machine following reactive hyperemia. Diabetic patients were found to have the highest levels of EMP31+; diabetic and nondiabetic men with ED were found to have significantly higher levels of EMP62+ than nondiabetic men without ED. The EMP62/EMP31 ratio, an index of endothelial activation (high ratio) or apoptosis (low ratio), was lowest in diabetic men with ED (0.20). In the whole group of 54 men with ED (diabetic and nondiabetic), there was an inverse correlation between FMD and the number of circulating EMPs (P < 0.05). The presence of diabetes in subjects with ED is associated with a different pattern of endothelial cell injury. The phenotypic assessment of EMPs in diabetic patients with ED is consistent with increased apoptotic activity.
- 1 June 2008
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 5 (6) , 1436-1442
Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction
Endothelial microparticles (EMPs) may play a role as biomarkers of vascular injury. EMPs are higher in men with diabetes diabetic men with erectile dysfunction (ED) than in nondiabetic potent men. The aim of this study was to quantize different phenotypic circulating EMP levels among diabetic and nondiabetic patients with ED, and to determine whether EMPs are released as a result of activation or apoptosis. We studied 30 type 2 diabetic and 24 nondiabetic subjects with symptomatic ED from at least 6 months, and 20 nondiabetic men without ED matched for age and weight with diabetic and nondiabetic subjects. Erectile function was assessed by completing the International Index of Erectile Function (IEEF)-5, which consists of Items 5, 15, 4, 2, and 7 from the full-scale IIEF-15. A score of 21 or less indicates the presence of ED. EMP levels in plasma were quantified by flow cytometry. Markers for apoptosis (platelet/endothelial cell adhesion molecule 1/CD31 antigen) and activation (E-selectin/CD62E antigen) were compared. Endothelium-dependent flow-mediated dilation (FMD) was evaluated in the right brachial artery with a high-resolution ultrasound machine following reactive hyperemia. Diabetic patients were found to have the highest levels of EMP31+; diabetic and nondiabetic men with ED were found to have significantly higher levels of EMP62+ than nondiabetic men without ED. The EMP62/EMP31 ratio, an index of endothelial activation (high ratio) or apoptosis (low ratio), was lowest in diabetic men with ED (0.20). In the whole group of 54 men with ED (diabetic and nondiabetic), there was an inverse correlation between FMD and the number of circulating EMPs (P < 0.05). The presence of diabetes in subjects with ED is associated with a different pattern of endothelial cell injury. The phenotypic assessment of EMPs in diabetic patients with ED is consistent with increased apoptotic activity.
- 24 November 2004
- Published by American Medical Association (AMA)
- Vol. 292 (20) , 2466-2467
Erectile Dysfunction in Obese Men—Reply
- 24 November 2004
- Published by American Medical Association (AMA)
- Vol. 292 (20) , 2466-2467
Erectile Dysfunction in Obese Men—Reply
- 1 March 2002
- Vol. 93 (3) , 172-4
[Hyperglycemia and vascular damage role of oxidative stress].
Diabetes mellitus is an important risk factor for cardiovascular disease and hyperglycaemia is being more and more acknowledged as a mediator of vessel damage. It is becoming increasingly clear that hyperglycaemia involves a number of different parameters (acute, chronic, and post-prandial hyperglycaemia), all of which contribute to the vascular damage caused by high glucose levels. High glucose levels are associated with the non-enzymatic glycation of both extra- and intracellular proteins, the accumulation of sorbitol via the aldose-reductase pathway, the activation of protein kinase C isoforms, and the reduced bioavailability of nitric oxide. The generation of reactive oxygen species may be a common downstream mechanism by means of which the multiple by-products of glucose exert their adverse effects on blood vessels.
- 1 March 2002
- Vol. 93 (3) , 172-4
[Hyperglycemia and vascular damage role of oxidative stress].
Diabetes mellitus is an important risk factor for cardiovascular disease and hyperglycaemia is being more and more acknowledged as a mediator of vessel damage. It is becoming increasingly clear that hyperglycaemia involves a number of different parameters (acute, chronic, and post-prandial hyperglycaemia), all of which contribute to the vascular damage caused by high glucose levels. High glucose levels are associated with the non-enzymatic glycation of both extra- and intracellular proteins, the accumulation of sorbitol via the aldose-reductase pathway, the activation of protein kinase C isoforms, and the reduced bioavailability of nitric oxide. The generation of reactive oxygen species may be a common downstream mechanism by means of which the multiple by-products of glucose exert their adverse effects on blood vessels.